SEC Form 4 · accession 0001179110-15-002175
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mathai Mammen
Officer — SVP, Research & Development
Period of report
Feb 5, 2015
Accepted (ET)
Feb 9, 2015 · 7:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 5, 2015 | A | 130,000 | $0.00 | A | 228,530 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 18,038 shares acquired in a pro rata distribution by Theravance, Inc. which relate to a performance stock award granted by Theravance, Inc. on February 11, 2011, for which the performance conditions were achieved on February 5, 2015 (and which will vest on February 20, 2016, subject to the reporting person's continued employment through such date).